Orthofix Medical (OFIX) to Release Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) will issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.32) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Orthofix Medical (NASDAQ:OFIX) last posted its earnings results on Tuesday, March 5th. The medical device company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.01. Orthofix Medical had a negative net margin of 20.28% and a negative return on equity of 10.63%. The company had revenue of $200.42 million for the quarter. On average, analysts expect Orthofix Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orthofix Medical Stock Performance

Shares of NASDAQ OFIX opened at $13.60 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.20 and a current ratio of 2.54. The company has a 50 day simple moving average of $13.62 and a 200-day simple moving average of $12.99. Orthofix Medical has a 1 year low of $9.57 and a 1 year high of $21.60.

Analyst Ratings Changes

OFIX has been the subject of several recent analyst reports. StockNews.com cut Orthofix Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, March 6th. Roth Mkm raised their price objective on Orthofix Medical from $12.00 to $15.00 and gave the stock a “neutral” rating in a research report on Thursday, March 7th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Orthofix Medical in a research report on Monday, April 22nd. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, Orthofix Medical has an average rating of “Hold” and a consensus target price of $15.50.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.